Obesity (Adiposity-Based Chronic Disease)

Overview

For most of the last century, obesity was treated as a behavioral problem — eat less, move more. That view is now considered obsolete (De Luca et al., Obesity Surgery, 2025). The American Medical Association classified obesity as a disease in 2013, and contemporary guidelines from the VA/DoD, the American College of Cardiology, the European Association for the Study of Obesity, the Lancet Commission, and the American Association of Clinical Endocrinology now define it as a chronic disease of dysfunctional adipose tissue (adiposopathy) driven by complex genetic, hormonal, neurological, environmental, and socioeconomic interactions (Singh et al., Advances in Therapy, 2025; Tandar et al., Nature Reviews Endocrinology, 2026). Twin, family, and adoption studies estimate obesity is 40%–70% heritable, and genome-wide studies have identified more than 1,100 genetic loci — many of which act on brain pathways that control appetite, reward, and energy expenditure (Singh et al., Advances in Therapy, 2025).

This biology explains the single most important and most misunderstood fact about obesity: the body defends its fat mass. When weight is lost, the hunger hormone ghrelin rises while the satiety hormones leptin, peptide YY, and GLP-1 fall, and resting energy expenditure can drop disproportionately — a coordinated "anti-starvation" response that drives weight regain (VA/DoD Clinical Practice Guideline, 2025). This is why roughly 80% of people who lose weight through lifestyle change alone regain about half of it within a year, and it is why obesity — like hypertension or diabetes — requires ongoing, often lifelong, treatment rather than a one-time fix (Singh et al., Advances in Therapy, 2025).

Obesity is also one of the defining public health crises of our time. An estimated 40.3% of U.S. adults have obesity and 9.4% have severe obesity (BMI ≥40), and in 2022 roughly 107 million American adults — 42.5% of the adult population — were living with obesity, projected to reach nearly 47% by 2035 (Emmerich et al., NCHS Data Brief, 2024; DeCleene et al., JAMA, 2026). Globally, more than 2.1 billion adults have overweight and obesity, and by 2050 the figure is forecast to exceed 3.8 billion — over half of all adults (GBD 2021 Adult BMI Collaborators, Lancet, 2025). Despite effective treatment, obesity remains one of the most undertreated diseases in medicine: fewer than 1%–2% of eligible patients undergo metabolic and bariatric surgery in any given year (Jirapinyo et al., ASGE-ESGE Guideline, 2024; Kurian et al., JAMA, 2024).

‍

Causes

Obesity results from a chronic imbalance between energy intake and expenditure, but that imbalance is produced by many interacting biological and environmental forces — not by a simple lack of discipline (Gadde et al., Journal of the American College of Cardiology, 2018):

• Genetics and epigenetics. Obesity is 40%–70% heritable; rare single-gene (monogenic) forms exist, but most obesity is polygenic, with over 1,100 gene variants influencing appetite, reward, and metabolism, many expressed in the brain (Singh et al., Advances in Therapy, 2025). Metabolic programming can begin in utero and be transmitted across generations (Gadde et al., Journal of the American College of Cardiology, 2018).

• Neurohormonal dysregulation. Imbalances in leptin, ghrelin, insulin, GLP-1, peptide YY, and other gut-brain signals disrupt the hypothalamic control of hunger and satiety and the dopaminergic reward system that governs eating behavior (Theilade et al., Diabetes, Obesity and Metabolism, 2021; De Luca et al., Obesity Surgery, 2025).

• Adiposopathy (dysfunctional fat tissue). Excess adipose tissue becomes a dysfunctional endocrine organ, secreting pro-inflammatory cytokines (TNF-α, IL-6) and driving chronic low-grade inflammation, insulin resistance, and metabolic dysfunction (VA/DoD Clinical Practice Guideline, 2025).

• Obesogenic environment. Easy access to calorie-dense food, food marketing, poor neighborhood walkability, sedentary work and transportation, and chronic stress all promote weight gain (Blüher, Nature Reviews Endocrinology, 2019).

• Medications and secondary causes. Certain antidepressants, antipsychotics, antihyperglycemics (e.g., insulin, sulfonylureas), and steroids promote weight gain, and endocrine disorders (hypothyroidism, hypercortisolism) or genetic syndromes can cause secondary obesity (Elmaleh-Sachs et al., JAMA, 2023).

‍

Risk Factors

• Family history / genetic predisposition — the strongest individual-level determinant (Singh et al., Advances in Therapy, 2025).

• Socioeconomic disadvantage — lower income, less education, food insecurity, and residential segregation are associated with higher obesity prevalence (Singh et al., Advances in Therapy, 2025).

• Obesogenic environment and sedentary lifestyle — diet quality, physical inactivity, and poor sleep (Elmaleh-Sachs et al., JAMA, 2023).

• Chronic stress and psychological factors — elevated cortisol and the bidirectional link between depression and obesity (Elmaleh-Sachs et al., JAMA, 2023).

• Weight-promoting medications — antidepressants, antipsychotics, insulin, and others (Elmaleh-Sachs et al., JAMA, 2023).

• Age, sex, and race/ethnicity — U.S. prevalence peaks in middle age and is highest among non-Hispanic Black women (56.9%), with substantial regional variation (DeCleene et al., JAMA, 2026).

• Childhood obesity — strongly predicts adult obesity, with earlier onset of complications (GBD 2021 Adult BMI Collaborators, Lancet, 2025).

‍

How Obesity Affects the Body

Obesity harms health through two distinct but overlapping mechanisms (VA/DoD Clinical Practice Guideline, 2025). The first is adiposopathy — dysfunctional fat tissue, especially visceral fat around the organs, that behaves as a diseased endocrine organ. It secretes pro-inflammatory cytokines and drives a chronic inflammatory state that produces insulin resistance, dyslipidemia, endothelial dysfunction, a hypercoagulable state, and abnormal lipid metabolism — the common soil of type 2 diabetes, atherosclerotic cardiovascular disease, fatty liver disease, chronic kidney disease, and several cancers (Lingvay et al., Lancet, 2024). The second is the mechanical burden of fat mass — the physical effect of excess tissue that damages weight-bearing joints (osteoarthritis), raises intra-abdominal pressure (gastroesophageal reflux disease and hiatal hernia), restricts breathing (obstructive sleep apnea, obesity hypoventilation), and causes venous stasis and lymphedema (VA/DoD Clinical Practice Guideline, 2025; Lingvay et al., Lancet, 2024). Importantly, visceral (central) adiposity is far more metabolically dangerous than subcutaneous fat, which is why two people with the same BMI can have very different health risk (Tandar et al., Nature Reviews Endocrinology, 2026).

‍

Complications

Obesity is linked to more than 200 chronic health conditions and reduces both lifespan and healthspan — with total years of life lost ranging from 5 to 20 depending on severity and comorbidity (VA/DoD Clinical Practice Guideline, 2025; Al-Khyatt, Handbook of Metabolic and Bariatric Surgery, 2022):

• Cardiometabolic — type 2 diabetes (up to ~43% prevalence in class III obesity), hypertension, dyslipidemia, metabolic syndrome, coronary artery disease, heart failure, stroke, and venous thromboembolism (VA/DoD Clinical Practice Guideline, 2025).

• Gastrointestinal / hepatic — gastroesophageal reflux disease, hiatal hernia, gallstone disease, and metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), a leading and growing cause of cirrhosis and liver transplantation (VA/DoD Clinical Practice Guideline, 2025). See our GERD / Acid Reflux and Hiatal & Paraesophageal Hernia pages.

• Respiratory — obstructive sleep apnea, obesity hypoventilation syndrome, and asthma (Lingvay et al., Lancet, 2024).

• Oncologic — obesity is the leading cause of cancer in nonsmokers and is associated with at least 13 cancers, including breast, endometrial, colorectal, esophageal, and kidney (VA/DoD Clinical Practice Guideline, 2025). Notably, bariatric surgery is associated with reduced cancer incidence and improved survival (VA/DoD Clinical Practice Guideline, 2025).

• Renal — glomerulosclerosis and chronic kidney disease, which independently predict the worst survival among obesity phenotypes (Tandar et al., Nature Reviews Endocrinology, 2026).

• Musculoskeletal — osteoarthritis, chronic back pain, and functional/mobility limitation (Al-Khyatt, Handbook of Metabolic and Bariatric Surgery, 2022).

• Reproductive/endocrine — polycystic ovary syndrome, infertility, and hypogonadism (Al-Khyatt, Handbook of Metabolic and Bariatric Surgery, 2022).

• Psychosocial — depression, anxiety, reduced quality of life, and pervasive weight stigma and discrimination that themselves worsen health (Lingvay et al., Lancet, 2024).

‍

Symptoms and Signs

Obesity is often clinically silent in its early stages and is defined by excess adiposity rather than by symptoms, which is why diagnosis relies on measurement (VA/DoD Clinical Practice Guideline, 2025). When symptoms occur, they commonly reflect the complications rather than the adiposity itself (Al-Khyatt, Handbook of Metabolic and Bariatric Surgery, 2022):

• Increased body fat and weight gain, often central (abdominal) (Tandar et al., Nature Reviews Endocrinology, 2026).

• Reduced exercise tolerance, breathlessness on exertion, and fatigue (Al-Khyatt, Handbook of Metabolic and Bariatric Surgery, 2022).

• Snoring, witnessed apneas, and daytime sleepiness (sleep apnea) (Lingvay et al., Lancet, 2024).

• Heartburn and regurgitation (reflux) and joint pain (osteoarthritis) (VA/DoD Clinical Practice Guideline, 2025).

• Signs of insulin resistance such as acanthosis nigricans, and symptoms of established diabetes (thirst, polyuria) (Lister et al., Nature Reviews Disease Primers, 2023).

• Low mood, anxiety, and impaired quality of life (Lingvay et al., Lancet, 2024).

‍

Diagnosis

Obesity has traditionally been diagnosed using body mass index (BMI) — weight in kilograms divided by height in meters squared — with the WHO classifying overweight as 25–29.9, class I obesity as 30–34.9, class II as 35–39.9, and class III as ≥40 (Elmaleh-Sachs et al., JAMA, 2023). For Asian populations, lower thresholds apply (obesity defined at BMI ≥27.5) because cardiometabolic disease occurs at lower BMIs (Tandar et al., Nature Reviews Endocrinology, 2026).

However, BMI alone is no longer considered sufficient to diagnose obesity in an individual, and this is central to modern, authoritative obesity care (Elmaleh-Sachs et al., JAMA, 2023). BMI does not distinguish fat from muscle, does not capture fat distribution, and has a pooled sensitivity of only about 50% for excess adiposity — meaning it misses roughly half of people with a high body-fat percentage (Tandar et al., Nature Reviews Endocrinology, 2026). In large body-composition datasets, about 80% of people labeled merely "overweight" by BMI actually have a body-fat percentage in the obese range (Salmón-Gómez et al., Reviews in Endocrine and Metabolic Disorders, 2023). Contemporary guidelines therefore recommend:

• Anthropometrics beyond BMI — waist circumference (≥102 cm men, ≥88 cm women, with lower ethnic-specific cutoffs) and waist-to-height ratio (≥0.5) to capture dangerous central/visceral adiposity (Tandar et al., Nature Reviews Endocrinology, 2026; Gilbert et al., ACC Expert Consensus, 2025).

• Direct body-composition measurement when available — DXA or bioimpedance to quantify fat mass, lean mass, and visceral fat (Gilbert et al., ACC Expert Consensus, 2025).

• A complications-centric staging approach — systems such as the Edmonton Obesity Staging System grade severity by organ dysfunction and functional impairment, and higher stages predict higher mortality independent of BMI (Elmaleh-Sachs et al., JAMA, 2023; Tandar et al., Nature Reviews Endocrinology, 2026).

• Assessment for secondary causes and comorbidities — screening for hypothyroidism, hypercortisolism, binge eating disorder, and weight-promoting medications, plus labs and studies for diabetes, lipids, liver disease, and sleep apnea (Elmaleh-Sachs et al., JAMA, 2023).

‍

Differential Diagnosis

• Secondary (endocrine) obesity — hypothyroidism, Cushing syndrome/hypercortisolism, and growth hormone deficiency (Elmaleh-Sachs et al., JAMA, 2023).

• Medication-induced weight gain — antipsychotics, some antidepressants, insulin, sulfonylureas, corticosteroids (Elmaleh-Sachs et al., JAMA, 2023).

• Genetic/syndromic obesity — monogenic (e.g., MC4R, POMC, leptin pathway) and syndromic forms such as Prader-Willi (Singh et al., Advances in Therapy, 2025).

• Hypothalamic obesity — from tumor, surgery, or radiation affecting appetite regulation (Gadde et al., Journal of the American College of Cardiology, 2018).

• Edematous states / fluid overload — which raise weight without excess adiposity and can confound BMI (Tandar et al., Nature Reviews Endocrinology, 2026).

• Lipedema — a sex-specific adipose tissue disorder distinct from generalized obesity (Tandar et al., Nature Reviews Endocrinology, 2026).

‍

Lifestyle Modifications

Lifestyle change is the foundation of all obesity treatment and is combined with — not replaced by — medication or surgery (Jirapinyo et al., ASGE-ESGE Guideline, 2024):

• Nutrition — a sustainable, calorie-reduced dietary pattern tailored to patient preference; there is no single "best" diet, and adherence matters most (Elmaleh-Sachs et al., JAMA, 2023).

• Physical activity — critical for weight-loss maintenance and cardiometabolic health, though exercise alone typically produces only modest weight loss (2–3 kg) (Elmaleh-Sachs et al., JAMA, 2023).

• Structured behavioral programs — ideally ≥14 sessions over 6 months, incorporating self-monitoring, goal-setting, and problem-solving, producing 5%–10% weight loss (Elmaleh-Sachs et al., JAMA, 2023).

• Sleep, stress, and mental health — optimizing sleep and addressing depression, anxiety, and disordered eating (Elmaleh-Sachs et al., JAMA, 2023).

• Protein and resistance training — especially important during rapid weight loss to preserve lean muscle mass.

A candid, evidence-based expectation is essential: comprehensive lifestyle intervention produces meaningful 3%–5% (sometimes 5%–10%) weight loss, but 25% or more of participants regain weight by two years because of the body's biological defense of fat mass — which is precisely why obesity is managed as a chronic disease (Elmaleh-Sachs et al., JAMA, 2023; Schumacher et al., Diabetes Care, 2026).

‍

Treatment Options

There are three evidence-based treatment modalities, used alone or in combination and escalated by disease severity and complication burden (Schumacher et al., Diabetes Care, 2026). The guiding principle is that the most effective treatment is matched to the individual — and that the three are complementary tools on a spectrum, not competitors:

• Lifestyle modification (foundational, all patients) — ~3%–5% weight loss alone; the base of every treatment plan (Schumacher et al., Diabetes Care, 2026).

• Anti-obesity medications (>10% with newer agents). Six FDA-approved drugs for long-term use: the GLP-1 receptor agonists semaglutide (Wegovy) and liraglutide (Saxenda), the GIP/GLP-1 dual agonist tirzepatide (Zepbound), plus phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and orlistat (Elmaleh-Sachs et al., JAMA, 2023). Tirzepatide produces the greatest medication weight loss — about 21% at 72 weeks (Elmaleh-Sachs et al., JAMA, 2023). Wegovy is FDA-approved for chronic weight management and to reduce cardiovascular events in adults with established cardiovascular disease and overweight/obesity, and Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity (FDA Orange Book, 2025). These medications require ongoing use — weight is typically regained after discontinuation (Chumakova-Orin et al., Surgery for Obesity and Related Diseases, 2026).

• Endoscopic bariatric therapies (10%–13%). Intragastric balloons and endoscopic sleeve gastroplasty offer a less invasive option for appropriate patients (Elmaleh-Sachs et al., JAMA, 2023). See our Endoscopic Sleeve Gastroplasty, Gastric Balloon, and Allurion Balloon pages.

• Metabolic and bariatric surgery (25%–35%, the most effective and durable). Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass account for ~80% of procedures, with SADI-S, biliopancreatic diversion with duodenal switch, and emerging options for the highest-BMI patients (Schumacher et al., Diabetes Care, 2026). Per the 2022 ASMBS/IFSO guidelines, surgery is recommended for BMI ≥35 regardless of comorbidities, and for BMI 30–34.9 with metabolic disease such as inadequately controlled type 2 diabetes (Kurian et al., JAMA, 2024). See our Sleeve Gastrectomy, Gastric Bypass, SADI-S, Duodenal Switch, MaGDI, and Revision Surgery pages.

The modern, authoritative framing is integration, not rivalry: GLP-1 medications and surgery are complementary, with drugs useful before surgery to optimize higher-risk patients and after surgery to treat weight regain, while bariatric programs serve as the multidisciplinary "medical home" coordinating the whole continuum of care (Chumakova-Orin et al., Surgery for Obesity and Related Diseases, 2026).

To learn how the oral options differ from one another, see Phentermine, Qsymia, Contrave, Orlistat: Understanding Oral Weight Loss Medications; for what may be coming next, read The Future of GLP-1 Medications: Pills, Triple Agonists, and What's Coming Next.

‍

When to See a Doctor

Anyone with a BMI of 30 or higher, or a BMI of 25–29.9 with weight-related health problems (type 2 diabetes, hypertension, sleep apnea, fatty liver, reflux, or joint disease), should discuss obesity as a treatable medical condition with a physician (Elmaleh-Sachs et al., JAMA, 2023). Evaluation is especially important for anyone who has tried repeatedly to lose weight through diet and exercise without durable success — this is the expected biology of the disease, not a personal failure, and effective medical and surgical treatments exist (Singh et al., Advances in Therapy, 2025).

‍

When to Seek Treatment

Earlier treatment yields better outcomes, because the mortality and cardiovascular benefit of definitive treatment is greatest when metabolic disease is caught early — for example, the survival advantage of surgery over medication is most pronounced in patients with a shorter duration of diabetes (Dicker et al., JAMA Network Open, 2024). Patients with class II–III obesity (BMI ≥35), with BMI ≥30 plus type 2 diabetes or other serious comorbidity, or with obesity-related complications that are progressing despite lifestyle change and medication should be referred for comprehensive evaluation, including consideration of metabolic and bariatric surgery (Kurian et al., JAMA, 2024). Surgery can also serve as a bridge to joint replacement, hernia repair, or organ transplantation (Kurian et al., JAMA, 2024).

‍

Long-Term Outlook

Because obesity is chronic and the body biologically defends its weight, long-term success depends on ongoing, individualized care rather than any single intervention (Singh et al., Advances in Therapy, 2025). Lifestyle change alone is frequently undone by weight regain; medications work while they are taken; and surgery produces the most durable results — 23%–27% total weight loss sustained at 10 years for sleeve and bypass — but a minority of patients experience weight regain and benefit from medication or revision (Brosnihan et al., The American Surgeon, 2025). The modern long-term strategy treats obesity like diabetes or hypertension: continuous monitoring, escalation and combination of therapies over time (lifestyle + medication + surgery as needed), and management of complications — a model in which the metabolic and bariatric surgery program functions as the patient's long-term medical home (Chumakova-Orin et al., Surgery for Obesity and Related Diseases, 2026).

Related Reading and Videos

Read more in our articles Why Obesity Is a Metabolic Disease — Not a Willpower Problem and Why Diets Fail: The Biology Behind Weight Loss, Regain, and Metabolic Adaptation. Watch The Hidden Dangers of Obesity — And Why Treatment Changes Everything and Obesity Is a Disease, Not a Failure: What That Really Means on our video library.

Prognosis

Untreated, obesity is a progressive disease that accumulates comorbidities and shortens life, with total years lost ranging from 5 to 20 depending on severity (Al-Khyatt, Handbook of Metabolic and Bariatric Surgery, 2022). The prognosis changes dramatically with effective treatment. Even 5%–10% weight loss improves blood pressure, glycemic control, and lipids (Elmaleh-Sachs et al., JAMA, 2023). The greatest prognostic improvement comes from metabolic and bariatric surgery: compared with GLP-1 receptor agonists, surgery is associated with a 43% lower risk of all-cause mortality, 35% lower risk of major adverse cardiovascular events, and 55% lower risk of heart failure (Cordova and Málaga, Surgery for Obesity and Related Diseases, 2026). In a large cohort with nearly 6 years of follow-up, surgery was associated with a 10-year all-cause mortality of 9.0% versus 12.4% with GLP-1 therapy, along with substantially lower risks of kidney and eye disease (Gasoyan et al., Nature Medicine, 2025).

‍

Why Choose Dr. de la Cruz-Muñoz

Obesity is not a willpower problem — it is a chronic, biological disease, and it deserves a physician who treats it that way. Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, is a board-certified minimally invasive bariatric and metabolic surgeon and a Diplomate of the American Board of Obesity Medicine, which means he is formally trained in the full spectrum of obesity care — not only the operating room. That dual expertise matters: the most authoritative guidelines now emphasize that obesity is best managed within a comprehensive, longitudinal program that coordinates nutrition, behavioral support, anti-obesity medications (including GLP-1 therapies), endoscopic options, and the full range of surgical procedures, rather than offering a single one-size-fits-all solution. His Miami practice is built around exactly this model for over 25 years: careful, individualized assessment of each patient's adiposity, metabolic health, and complication burden; honest, evidence-based counseling about what each treatment can and cannot deliver; and a complete surgical armamentarium — Sleeve Gastrectomy, Roux-en-Y gastric bypass, SADI-S, duodenal switch, magnetic duodeno-ileostomy with sleeve (MaGDI), revisional and conversion surgery, endoscopic sleeve gastroplasty, and intragastric balloons — matched to the right patient rather than the other way around. Because he also treats the downstream consequences of obesity, including reflux disease, hiatal and paraesophageal hernia, and metabolic disease, patients receive coordinated care across the entire continuum of their condition. For patients across South Florida who are tired of being told to simply "try harder," that combination of obesity-medicine expertise, surgical mastery, and a chronic-disease philosophy is what makes this practice a trusted destination.

‍

Dr. de la Cruz-Muñoz has been performing bariatric surgery for over 25 years and has completed more than 9,000 bariatric operations — a volume few surgeons reach.